CVRx (CVRX) to Release Earnings on Thursday

CVRx (NASDAQ:CVRX) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $14.68 million for the quarter.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Price Performance

Shares of NASDAQ CVRX opened at $7.43 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 12.06 and a quick ratio of 10.23. The company has a market cap of $193.60 million, a price-to-earnings ratio of -2.76 and a beta of 1.39. The stock’s 50-day moving average is $9.64 and its two-hundred day moving average is $12.68. CVRx has a 1-year low of $5.81 and a 1-year high of $18.55.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CVRX. William Blair raised CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. Lake Street Capital lowered their target price on shares of CVRx from $19.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, April 8th. Canaccord Genuity Group dropped their target price on shares of CVRx from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, April 8th. Craig Hallum boosted their price target on shares of CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, January 17th. Finally, Piper Sandler raised their price objective on CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $17.60.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.